• Explore /
  • Poster
  • / Outcomes in patients (pts) with advanced renal cell carcinoma (aRCC) who discontinued (DC) first-line nivolumab + ipilimumab (N+I) or sunitinib (S) due to treatment-related adverse events (TRAEs) in CheckMate 214.

Outcomes in patients (pts) with advanced renal cell carcinoma (aRCC) who discontinued (DC) first-line nivolumab + ipilimumab (N+I) or sunitinib (S) due to treatment-related adverse events (TRAEs) in CheckMate 214.

Abstract Poster

Authors

null

Nizar M. Tannir

The University of Texas MD Anderson Cancer Center, Houston, TX

Nizar M. Tannir , Robert J. Motzer , Elizabeth R. Plimack , David F. McDermott , Philippe Barthelemy , Camillo Porta , Saby George , Thomas Powles , Frede Donskov , Christian K. Kollmannsberger , Howard Gurney , Asim Amin , Marc-Oliver Grimm , Brian I. Rini , Yoshihiko Tomita , M. Brent McHenry , Sabeen Fatima Mekan , Bernard Escudier , Hans J. Hammers

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Renal Cell Cancer

Track

Renal Cell Cancer

Sub Track

Renal Cell Cancer

Clinical Trial Registration Number

NCT02231749

Citation

J Clin Oncol 37, 2019 (suppl 7S; abstr 581)

DOI

10.1200/JCO.2019.37.7_suppl.581

Abstract #

581

Poster Bd #

E20

Abstract Disclosures

Similar Posters

First Author: Nizar M. Tannir

First Author: Robert J. Motzer

First Author: Nizar M. Tannir

First Author: Nusrat Jahan